Cadherin
Cadherins are a family of calcium-dependent cell adhesion molecules and transmembrane glycoproteins that play a crucial role in maintaining tissue architecture and cellular communication. Key members of the cadherin family include E-cadherin (CDH1), N-cadherin (CDH2), and P-cadherin (CDH3), etc. Cadherins mediate cell-cell adhesion through homophilic interactions, forming adherens junctions that connect to the actin cytoskeleton via catenins, thus influencing cellular signaling pathways related to proliferation, differentiation, and migration[1].
cadherins are involved in various signaling pathways, such as the Wnt and Notch pathways, which are critical for development and tissue homeostasis. Cadherins often bind to β-catenin (CTNNB1) through the catenin-binding domain. The catenin-binding domain of cadherin is crucial in cadherin function and it plays an important role in maintaining epithelial integrity. Dysregulation of cadherin expression is associated with several diseases, particularly cancer, such as pancreatic cancer, melanoma, hepatocellular carcinoma, glioblastoma, breast and gastric cancers. The epigenetic silencing of cadherins through mechanisms like DNA methylation further exacerbates this issue in tumor progression. Understanding cadherins' roles in cellular dynamics provides insights into potential therapeutic targets for cancer and other diseases characterized by altered cell adhesion[1].
cadherins are involved in various signaling pathways, such as the Wnt and Notch pathways, which are critical for development and tissue homeostasis. Cadherins often bind to β-catenin (CTNNB1) through the catenin-binding domain. The catenin-binding domain of cadherin is crucial in cadherin function and it plays an important role in maintaining epithelial integrity. Dysregulation of cadherin expression is associated with several diseases, particularly cancer, such as pancreatic cancer, melanoma, hepatocellular carcinoma, glioblastoma, breast and gastric cancers. The epigenetic silencing of cadherins through mechanisms like DNA methylation further exacerbates this issue in tumor progression. Understanding cadherins' roles in cellular dynamics provides insights into potential therapeutic targets for cancer and other diseases characterized by altered cell adhesion[1].
All Product Categories
-
Cadherin Related Products (72)
Related Products (72)
-
BAS00602705
0 ImagesBAS00602705 is an E-cadherin inhibitor. BAS00602705 exerts its function by blocking the trans-interactions of E-cadherin molecules within junctional complexes, without permanently altering E-cadherin expression levels. BAS00602705 significantly impairs invadopodia formation in pancreatic cancer cells. BAS00602705 can be used for the study of anti-invasive therapeutic strategies in cancers characterized by dysregulated E-cadherin-mediated invadopodia activity, such as pancreatic ductal adenocarcinoma (PDAC).
-
NKP608
0 ImagesNKP608 is a non-peptidic derivative of 4-aminopiperidine, a highly selective, orally active, neurokinin-1 (NK1) receptor antagonist with IC50 of 2.6 nM. NKP608 is active both in vitro and in vivo, showing extremely low affinity for NK2, NK3 receptors. NKP608 exerts its effects by blocking the NK₁ receptor, regulate cell proliferation and apoptosis, affect neurotransmitter functions and gastric mucosal repair mechanisms, and suppress the Wnt/β-catenin pathway in antitumor research. NKP608 is applicable to research related to various diseases, including cough, anxiety disorders, depression, gastric mucosal injury, and colorectal cancer.
-
CDH11-IN-1
0 ImagesCDH11-IN-1 is a CDH11 inhibitor. CDH11-IN-1 regulates CDH11-mediated biological pathways. CDH11-IN-1 can be used for research on cancer and rheumatoid arthritis.
-
7-Hydroxystaurosporine
0 ImagesCat. No.: HY-13661CAS No.: 112953-11-4Synonyms: UCN-01; KRX-06017-Hydroxystaurosporine (UCN-01), a derivative of Staurosporine (HY-15141), is a selective protein kinase C (PKC) inhibitor with antitumor activity. 7-hydroxystaurosporine induces apoptosis and inhibits cell proliferation in colon carcinoma and leukemia cells, suppresses invasion and migration in glioblastoma cells. 7-Hydroxystaurosporine exhibits efficacy in breast cancer xenograft mouse models. 7-Hydroxystaurosporine can be used for colon carcinoma, breast cancer, glioblastoma and leukemia research.
-
Murine Fibrinogen
0 ImagesCat. No.: HY-125864BCAS No.: 9001-32-5Murine Fibrinogen is a native fibrinogen derived from mouse plasma. Murine Fibrinogen acts as a cerebrovascular permeability enhancer. Murine Fibrinogen activates matrix metalloproteinase-9 (MMP-9), downregulates the expression of vascular endothelial cadherin (VE-cadherin), and upregulates the expression of plasmalemmal vesicle-associated protein-1 (PV-1). Murine Fibrinogen increases macromolecular leakage from pial veins, thereby disrupting the microvascular integrity of cerebral blood vessels. Murine Fibrinogen can be used in studies related to cerebrovascular dysfunction.
-
THR-123 TFA
0 ImagesCat. No.: HY-P11354APurity: 99.91%THR-123 TFA is an orally active ALK3 peptide agonist. THR-123 TFA has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 TFA suppresses inflammation, Apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 TFA can be used for the study of kidney fibrosis.
-
BAS00093476
0 ImagesBAS00093476 is an E-cadherin inhibitor. BAS00093476 exhibits inhibitory activity against E-cadherin-mediated cell-cell adhesion in human pancreatic tumor BxPC-3 cells. BAS00093476 can be applied to the research on the modulation of E-cadherin-mediated cell-cell adhesion in solid tumors expressing cadherins.
-
Sorafenib-13C,d3
0 ImagesSynonyms: Bay 43-9006-13C,d3Sorafenib-13C,d3 (Bay 43-9006-13C,d3) is the 13C, deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
Mg(Ⅱ)-EDTA disodium tetrahydrate
0 ImagesSynonyms: Ethylenediaminetetraacetic acid magnesium disodium tetrahydrateMg(Ⅱ)-EDTA (Ethylenediaminetetraacetic acid magnesium) disodium tetrahydrate is a divalent metal chelator and ferroptosis inducer. Mg (Ⅱ)-EDTA disodium tetrahydrate reduces E-cadherin expression by chelating Ca2+ on the surface of tumor cells, thereby triggering cell dissociation and inducing epithelial-mesenchymal transition (EMT). Mg (Ⅱ)-EDTA disodium tetrahydrate further chelates lysosomal iron to form EDTA-Fe, induces ferroptosis through the Fenton reaction, and synergistically enhances immune responses to inhibit tumor metastasis. Mg (Ⅱ)-EDTA (disodium tetrahydrate) can be used in tumor-related research.
-
LNSMGQD
0 ImagesLNSMGQD is a cyclic peptide fragment derived from desmoglein 1 (amino acids 81-86), which mimics trans-interactions and acts as part of the tandem peptide binding interface of desmoglein 2. LNSMGQD not only binds to desmoglein 1 and 3, but also effectively inhibits their homophilic trans-interactions, while reducing the probability of homophilic or heterophilic binding between desmoglein 2 and Dsc2, N-cadherin and E-cadherin. LNSMGQD is applicable to the research on disease mechanisms such as Crohn's disease and pemphigus vulgaris.
-
CQY684
0 ImagesCat. No.: HY-P991342Synonyms: PCA062 antibodyCQY684 (PCA062 antibody) is a monoclonal antibody targeting CDH3/P-cadherin, which locks P-cadherin in an X-dimer conformation and enhances the stability of this adhesion structure. CQY684 induces P-cadherin phosphorylation and promotes its dissociation from the cytoplasmic region of P-cadherin. As an endocytosis inducer and lysosome-targeting agent, CQY684 facilitates the internalization of the P-cadherin-CQY684 complex and improves the turnover efficiency of P-cadherin. CQY684 serves as a platform for the delivery of intracellular anticancer compounds, which is achieved through the targeted lysosomal transport of the antibody-P-cadherin complex. CQY684 is applicable to the research of breast cancer, esophageal cancer, and head and neck cancer.
-
(R)-MMP408
0 Images(R)-MMP408 is an isomer of MMP408 (HY-12093). MMP408 is an orally active MMP-12 inhibitor (IC50=2.0 nM for hMMP-12) that effectively interferes with the epithelial-mesenchymal transition (EMT) process. MMP408 significantly upregulates the expression of E-cadherin in nasal epithelial cells, while inhibiting mesenchymal markers such as vimentin, α-smooth muscle actin and fibronectin, thereby reversing the EMT phenotype. MMP408 is used in studies of airway remodeling-related diseases, including chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease (COPD) and asthma.
-
Nef-M1
0 ImagesNef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer.
-
Anti-CDH1/E-cadherin/CD324 Antibody
0 ImagesCat. No.: HY-P990362Purity: 99.90%Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
-
(Rac)-AAA
0 Images(Rac)-AAA is a regulator and inhibitor targeting GPR75. By blocking the 20-HETE-induced downregulation of GPR75 expression, (Rac)-AAA effectively inhibits the activation of key downstream signaling pathways including EGFR, AKT, NF-κB and FAK. (Rac)-AAA reverses 20-HETE-mediated epithelial-mesenchymal transition, which is specifically characterized by downregulating vimentin (vimentin), upregulating E-Cadherin, as well as reducing MMP-2 activity and cancer cell migration ability. (Rac)-AAA also abolishes the 20-HETE-induced upregulation of HIC-5 expression and anchorage-independent growth, and modulates the subcellular localization of PKC-α and phosphorylated AKT. (Rac)-AAA is investigated in androgen-independent prostate cancer (castration-resistant prostate cancer).
-
Sorafenib-d4
0 ImagesSynonyms: Bay 43-9006-d4Sorafenib-d4 (Bay 43-9006-d4) is the deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
BAS00132635
0 ImagesCat. No.: HY-178520CAS No.: 302926-99-4BAS00132635 (Compound AS9) is an E-cadherin inhibitor. BAS00132635 can block trans-interactions of E-cadherin molecules in junctional complexes and reduce the number of cancer cells exhibiting invadopodia. BAS00132635 can be used for the research of cancer, such as Pancreatic cancer.
-
SF-9-2
0 ImagesCat. No.: HY-175236CAS No.: 3053768-78-5SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research.
-
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1)
0 ImagesCat. No.: HY-P990248Purity: 98.53%Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonal antibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma.
